Ariella,
I'm not sure that that big downside risks still exist. Yes, there may be disappointment in the the quarterly earnings, but all biotechs have the issue of quarterly sales fluctuations. Sales for small biotechs in particular need to be viewed over 6 month and 1 year periods. If the stock does drop some for any reason, some of us will be accelerating our accumulation. I've been investing in biotechs forever and you can't emphasize enough the "patience" one needs. I've been disappointed in the past, but I've been recommending PARS to family and friends for over 1 year. It's always hard to predict cycles, but I think that biotechs will be in favor this next year, as many new products hit the market...If some semblance of a reasonable peace plan can be achieved soon, the Israeli companies would benefit as well.
If HU-211 does reach its potential, then I'll be building my winter home somewhere around Ashkelon.
Really appreciate the posts from you, David, Yosi, Gabe (from yahoo)...and others.
Regards,
Shep |
